Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)

The summary for the Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed): This funding opportunity is designed to support research in understanding how to engineer intrinsic characteristics of stem cell-derived islet cell products that can result in improved cell replacement therapy outcomes. Unlike cadaveric human islets, stem cell-derived islet cell products are generated from well-defined and highly controlled cell bank sources. Their banking, manufacturing, and quality control processes can be used to instill optimized cell characteristics resulting in more resilient and durable graft viability and function. This funding opportunity aims to stimulate studies on targets and pathways amenable to such engineering approaches and to encourage preclinical testing and validation of such strategies.This NOFO is associated with the Special Diabetes Program (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/type-1-diabetes-special-statutory-funding-program/about-special-diabetes-program) which funds research on the prevention, treatment, and cure of type 1 diabetes and its complications, including unique, innovative, and collaborative research consortia and clinical trials networks.

Federal Grant Title:	Engineering Improved Stem Cell-Derived Islet Cells for Replacement Therapies (R01 - Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-DK-26-306
Type of Funding:	Grant
CFDA Numbers:	93.847
CFDA Descriptions:	Information not provided
Current Application Deadline:	March 7th, 2026
Original Application Deadline:	March 7th, 2026
Posted Date:	December 3rd, 2025
Creation Date:	December 3rd, 2025
Archive Date:	April 10th, 2026
Total Program Funding:	$3,000,000
Maximum Federal Grant Award:	$500,000
Minimum Federal Grant Award:
Expected Number of Awards:	6
Cost Sharing or Matching:	No
Last Updated:	December 3rd, 2025

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Refer to Section III. Eligibility Information in the NOFO for additional information on eligibility.Foreign Organizations/International CollaborationsNon-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply.Foreign components, as defined in the NIH Grants Policy Statement, are not allowed.NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts. All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. This new requirement was effective, May 1, 2025.Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding. This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components, funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Grant Announcement Contact: Albert Hwa
[email protected]
[email protected]
Similar Government Grants: • Single Source Renewal for the Continuation of the Liver Cirrhosis Network: Scientific and ...; • Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Train...; • Diabetes Research Centers (P30 Clinical Trial Optional); • Limited Competition Renewal for the Continuation of the Liver Cirrhosis Network: Clinical ...; • Advancing Research on the Application of Digital Health Technology to the Management of Ty...; • Proteomic and Metabolomic Approaches to Diagnose Diabetes and Pre-Diabetes; • Molecular Therapy Core Centers; • Pilot and Feasibility Program in Human Islet Biology
More Grants from the National Institutes of Health: • Single Source Renewal for the Continuation of the Liver Cirrhosis Network: Scientific and ...; • NIGMS Institutional Biomedical Undergraduate Research Training (BURT) Program (T34); • Limited Competition: Outcomes of Electronic Medical Records and Genomics (eMERGE) Genomic ...; • Maximizing Investigators' Research Award (MIRA) (R35 - Clinical Trial Optional); • Institutional Network Award for Promoting Kidney, Urologic, and Hematologic Research Train...